The FDA has granted approval to Stealth Therapeutics' therapy targeting Barth syndrome, marking the first mitochondria-targeted treatment available for this rare genetic disorder. This regulatory milestone opens new avenues for patients suffering from a disease characterized by compromised cellular energy metabolism. The therapy's approval underscores advancing interest and investment in precision mitochondrial medicine.